Management of Renal Masses

Diagnostic Evaluation

The American College of Radiology recommends obtaining multiphase contrast-enhanced CT or MRI immediately to characterize renal masses, as ultrasound alone cannot reliably distinguish benign from malignant lesions or determine enhancement patterns 1, 3, 4
MRI demonstrates higher specificity than CT (68.1% vs 27.7%) for characterizing renal lesions and is particularly useful for hyperechoic masses that may represent fat-poor angiomyolipoma 4
The imaging must assess: degree and pattern of enhancement, presence/absence of macroscopic fat, complexity, anatomic relationships, and clinical stage 1

The American Urological Association recommends obtaining a comprehensive metabolic panel with calculated GFR, complete blood count, urinalysis with assessment for proteinuria, and chest imaging (chest X-ray or CT) for metastatic evaluation before any intervention decision 1, 2
Assign CKD stage based on GFR and proteinuria to guide nephron-sparing decisions 1, 2

Consider renal mass biopsy (RMB) for cT1b masses, as it has excellent diagnostic accuracy: 97% sensitivity, 94% specificity, 99% positive predictive value, and 92.4% are contributive 5, 6, 1, 2
RMB should be strongly considered when imaging suggests a benign mass (such as possible fat-poor AML given hyperechoic appearance) 3, 4

The American Urological Association recommends partial nephrectomy as the standard of care for cT1b (4.3 cm) masses when intervention is indicated, prioritizing nephron-sparing approaches to minimize CKD risk and preserve long-term renal function 6, 2, 7
Radical nephrectomy remains an alternative standard if tumor location is unfavorable for partial nephrectomy, patient has increased surgical risk, or imaging/biopsy suggests aggressive features requiring wider excision 7, 2, 8

Prioritize negative surgical margins while minimizing normal parenchyma removal 6, 2
Avoid prolonged warm ischemia to preserve renal function 6, 2
Perform lymph node dissection only if clinically concerning lymphadenopathy present 6, 2

A urologist must lead comprehensive counseling covering tumor-specific oncologic risk, most common/serious urologic and non-urologic morbidities of each treatment pathway, impact of patient age, comorbidities, frailty, and life expectancy, and renal functional recovery implications 1, 2
Consider genetic counseling if patient ≤46 years old for hereditary RCC syndromes 2